This document provides an overview of a pharmaceutical company. It discusses the company's global reach across 21 countries, its portfolio of over 200 products in 17 therapeutic areas, and its corporate social responsibility programs in education and vision care. Key financial details are given, such as gross sales increasing from INR 105 crores to INR 124 crores from 2013-14 to 2015-16, with net profits of INR 10 crores and dividends of INR 2 per share in 2015-16. The company's future plans focus on new drug delivery systems, increased R&D spending, leveraging growth across markets, and boosting customers, market share and productivity.
